J9371 — Injection, vincristine sulfate liposome, 1 mg
J9371 is a HCPCS Level II code for injection, vincristine sulfate liposome, 1 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on June 30, 2024 and is not valid on new claims.
This code has been terminated
CMS terminated J9371 on June 30, 2024. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J9371
- Long descriptor
- Injection, vincristine sulfate liposome, 1 mg
- Short descriptor
- Inj, vincristine sul lip 1mg
- Added
- January 1, 2014
- Terminated
- June 30, 2024
- BETOS
- O1D
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J9371
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J9371 is not quite right, the correct code is very often within a few positions of it.
- J9355Injection, trastuzumab, excludes biosimilar, 10 mg
- J9356Injection, trastuzumab, 10 mg and hyaluronidase-oysk
- J9357Injection, valrubicin, intravesical, 200 mg
- J9358Injection, fam-trastuzumab deruxtecan-nxki, 1 mg
- J9359Injection, loncastuximab tesirine-lpyl, 0.075 mg
- J9360Injection, vinblastine sulfate, 1 mg
- J9361Injection, efbemalenograstim alfa-vuxw, 0.5 mg
- J9370Vincristine sulfate, 1 mg
- J9376Injection, pozelimab-bbfg, 1 mg
- J9380Injection, teclistamab-cqyv, 0.5 mg
- J9381Injection, teplizumab-mzwv, 5 mcg
- J9382Injection, zenocutuzumab-zbco, 1 mg
- J9390Injection, vinorelbine tartrate, 10 mg
- J9393Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg
- J9394Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg
- J9395Injection, fulvestrant, 25 mg
Questions about J9371
What is HCPCS code J9371?
J9371 is a HCPCS Level II code for injection, vincristine sulfate liposome, 1 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J9371?
The CMS HCPCS file marks J9371 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is J9371 still valid?
No. J9371 was terminated on June 30, 2024 and should not be used on new claims.